Omeros Corp (OMER) — SEC Filings
Omeros Corp (OMER) — 29 SEC filings. Latest: ARS (Apr 30, 2026). Includes 12 8-K, 6 10-Q, 2 DEF 14A.
Overview
Omeros Corp (OMER) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Omeros Corporation reported a net loss of $30.917 million for the three months ended September 30, 2025, a slight improvement from the $32.232 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $89.801 million, significantly better than the $1
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 1 bullish, 26 neutral, 2 mixed. The dominant filing sentiment for Omeros Corp is neutral.
Filing Type Overview
Omeros Corp (OMER) has filed 1 ARS, 12 8-K, 6 10-Q, 2 DEF 14A, 1 8-K/A, 1 10-K/A, 2 10-K, 2 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of OMER's 21 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | Not Disclosed |
| Net Income | -$30.917M |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | $2.395M |
| Operating Margin | Not Disclosed |
| Total Assets | $185.706M |
| Total Debt | $256.591M |
Key Executives
- GREGORY A. DEMOPULOS, M.D.
- Gregory A. Demopulos
- Thomas J. Cable
- Dr. Christina Chan
- Mr. Gregory T. Schiffman
- Dr. Anissa Brown
- Gregory A. Demopulos, M.D.
Industry Context
Omeros operates in the highly competitive biopharmaceutical industry, characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. The sector is driven by innovation in drug discovery and the ability to navigate complex clinical trials and approval processes. Companies often rely on strategic partnerships and licensing agreements to fund development and access broader markets, especially when facing liquidity constraints.
Top Tags
financials (6) · 10-Q (4) · pharmaceuticals (4) · Biotechnology (3) · Pharmaceuticals (3) · material-agreement (3) · Drug Development (2) · Clinical Trials (2) · filing (2) · 8-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $30.917M | Improved from $32.232M in Q3 2024 |
| Net Loss (YTD Q3 2025) | $89.801M | Improved from $125.457M in YTD Q3 2024 |
| R&D Expenses (Q3 2025) | $15.995M | Decreased from $24.084M in Q3 2024 |
| SG&A Expenses (Q3 2025) | $10.397M | Decreased from $11.323M in Q3 2024 |
| Cash and Cash Equivalents | $2.395M | As of September 30, 2025, down from $3.400M at Dec 31, 2024 |
| Upfront/Near-term Milestone Payments | $340.0M | Expected from Novo Nordisk APLA |
| Payment at APLA Closing | $240.0M | Expected from Novo Nordisk in Q4 2025 |
| Total Potential Milestone Payments | $1.71B | From Novo Nordisk APLA, including development, approval, and sales milestones |
| Common Shares Outstanding | 70,073,622 | As of September 30, 2025, increased from 58,044,465 at Dec 31, 2024 |
| Total Shareholders' Deficit (in thousands) | (220,478) | As of September 30, 2025, worsened from (182,609) at Dec 31, 2024 |
| Net loss for Q2 2025 | $25.4M | Reduced from $56.0M in Q2 2024 |
| Net loss for H1 2025 | $58.9M | Reduced from $93.2M in H1 2024 |
| Research and development expenses Q2 2025 | $22.0M | Decreased from $45.3M in Q2 2024 |
| Cash and cash equivalents at June 30, 2025 | $1.9M | Decreased from $3.4M at Dec 31, 2024 |
| Short-term investments at June 30, 2025 | $26.8M | Decreased from $86.7M at Dec 31, 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Omeros Corp (OMER)?
Omeros Corp has 29 recent SEC filings from Jan 2024 to Apr 2026, including 12 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of OMER filings?
Across 29 filings, the sentiment breakdown is: 1 bullish, 26 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Omeros Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Omeros Corp (OMER) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Omeros Corp?
Key financial highlights from Omeros Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for OMER?
The investment thesis for OMER includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Omeros Corp?
Key executives identified across Omeros Corp's filings include GREGORY A. DEMOPULOS, M.D., Gregory A. Demopulos, Thomas J. Cable, Dr. Christina Chan, Mr. Gregory T. Schiffman and 2 others.
What are the main risk factors for Omeros Corp stock?
Of OMER's 21 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Omeros Corp?
Forward guidance and predictions for Omeros Corp are extracted from SEC filings as they are enriched.